Half-year Report

RNS Number : 3265R
MGC Pharmaceuticals Limited
28 February 2023
 

MGC Pharmaceuticals Ltd.

Half Year Financial Report

28 February 2023

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ') , a European based bio-pharma company specialising in the production and development of phytomedicines, has today published its half year financial report for the period to 31 December 2022.

The report can be found following the link below:

https://www.asx.com.au/asxpdf/20230228/pdf/45m5r4hpgs6nb8.pdf

--Ends--

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.eu

MGC Pharmaceuticals Ltd

Company Secretary

+61 8 6382 3390

info@mgcpharma.eu  

UK Financial and Corporate Advisor

SW4 Partners

Rupert Fane / Nilesh Patel

+44 7810 056 104

rupert@sw4partners.com / nilesh@sw4partners.com

UK Broker

Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors

Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCGZGZZLRFGFZG
UK 100

Latest directors dealings